Kuros Biosciences Ltd.
Develops biologic technologies for tissue repair and bone regeneration.
KURN | SW
Overview
Corporate Details
- ISIN(s):
- CH0325814116
- LEI:
- 5299006U5POB2AVTT709
- Country:
- Switzerland
- Address:
- Wagisstraße 25, 8952 Schlieren
- Website:
- https://kurosbio.com/
- Sector:
- Manufacturing
Description
Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-03-16 07:00 |
Kuros Biosciences reports results for the full year 2021
|
English | 47.8 KB | ||
| 2022-02-03 07:00 |
Kuros Biosciencess MagnetOs Granules cleared by FDA for expanded spinal indicat…
|
English | 16.4 KB | ||
| 2022-01-20 07:00 |
Kuros Biosciences publishes first-in-human clinical data for Fibrin-PTH (KUR-11…
|
English | 14.2 KB | ||
| 2021-10-26 07:00 |
Kuros Biosciences reports continued increase in MagnetOs U.S. sales
|
English | 13.7 KB | ||
| 2021-09-28 07:00 |
Kuros Biosciences to showcase new MagnetOs products at NASS 2021 Annual Meeting
|
English | 12.7 KB | ||
| 2021-09-09 07:00 |
Kuros Biosciences Announces FDA 510(k) Clearance for MagnetOs Easypack PuttyHea…
|
English | 14.8 KB | ||
| 2021-08-11 07:00 |
Kuros Biosciences Reports Results for First Half 2021
|
English | 44.8 KB | ||
| 2021-07-15 07:00 |
Kuros to receive $7 million up front and potentially $166.5 million in future r…
|
English | 13.3 KB | ||
| 2021-06-22 07:00 |
Kuros Biosciences announces publication of data on MagnetOs in eCM Journal link…
|
English | 16.7 KB | ||
| 2021-06-17 07:00 |
Kuros Biosciences to present at upcoming U.S. spine conferences
|
English | 17.7 KB | ||
| 2021-06-02 07:00 |
Kuros Biosciencess commercial roll-out of MagnetOs bone graft exceeds expectati…
|
English | 14.3 KB | ||
| 2021-05-17 07:00 |
Kuros to receive $4 million milestone payment from Checkmate Pharmaceuticals
|
English | 11.0 KB | ||
| 2021-05-05 07:00 |
Kuros Biosciences strengthens its patent position on use of Fibrin-PTH in spina…
|
English | 12.7 KB | ||
| 2018-05-14 13:03 |
Kuros Biosciences AG (KURN-CH): Differentiated orthobiologics for spinal fusion:
|
English | 16.0 KB | ||
| 2016-08-10 07:00 |
Kuros appoints Philippe Saudan as Chief Development Officer
|
English | 6.3 KB |
Automate Your Workflow. Get a real-time feed of all Kuros Biosciences Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kuros Biosciences Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kuros Biosciences Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-23 | N/A | Executive member | Sell | None | 1,264,800.00 CHF |
| 2025-04-17 | N/A | Executive member | Sell | None | 13,344.49 CHF |
| 2025-03-18 | N/A | Non-Executive member | Buy | None | 38,200.00 CHF |
| 2024-12-11 | N/A | Executive member | Sell | None | 4,702,500.00 CHF |
| 2024-11-15 | N/A | Non-Executive member | Buy | None | 925,210.00 CHF |
| 2024-11-14 | N/A | Non-Executive member | Sell | None | 592,000.00 CHF |
| 2024-11-12 | N/A | Executive member | Sell | None | 13,890.86 CHF |
| 2024-09-25 | N/A | Executive member | Sell | None | 8,226,000.00 CHF |
| 2024-09-25 | N/A | Non-Executive member | Sell | None | 3,656,000.00 CHF |
| 2024-09-24 | N/A | Non-Executive member | Buy | None | 223,720.00 CHF |
Peer Companies
